EMA Panel Backs Baricitinib for Moderate-to-Severe Atopic Dermatitis EMA Panel Backs Baricitinib for Moderate-to-Severe Atopic Dermatitis

Baricitinib (Olumiant) would be the first JAK inhibitor (and oral medicine) indicated for adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.International Approvals
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Dermatology News Alert Source Type: news